Cover Image
市場調查報告書

ObeTherapy Biotechnology:產品平台分析

ObeTherapy Biotechnology - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 257872
出版日期 內容資訊 英文 23 Pages
訂單完成後即時交付
價格
Back to Top
ObeTherapy Biotechnology:產品平台分析 ObeTherapy Biotechnology - Product Pipeline Review - 2015
出版日期: 2015年08月31日 內容資訊: 英文 23 Pages
簡介

ObeTherapy Biotechnology 是致力於發明、研發肥胖和高膽固醇症、第二型糖尿病之治療藥的生物科技企業。該公司同時向Genopole申請促進公共研究部門上的大規模生物學性活動之發。

本報告提供ObeTherapy Biotechnology 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

ObeTherapy Biotechnology的基本資料

  • ObeTherapy Biotechnology概要
  • 主要資訊
  • 企業資料

ObeTherapy Biotechnology:R&D概要

  • 主要的治療範圍

ObeTherapy Biotechnology:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

ObeTherapy Biotechnology:開發中產品概況

  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

ObeTherapy Biotechnology:藥物簡介

  • Drugs to Inhibit Apobec-1 for Obesity
  • OBE-1999
  • OBE-2000
  • OBE-2001
  • OBE-2002
  • Lipid Absorption Inhibitor

ObeTherapy Biotechnology:開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

ObeTherapy Biotechnology:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07375CDB

Summary

Global Markets Direct's, 'ObeTherapy Biotechnology - Product Pipeline Review - 2015', provides an overview of the ObeTherapy Biotechnology's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ObeTherapy Biotechnology's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of ObeTherapy Biotechnology including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of ObeTherapy Biotechnology's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the ObeTherapy Biotechnology's pipeline products

Reasons to buy

  • Evaluate ObeTherapy Biotechnology's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of ObeTherapy Biotechnology in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the ObeTherapy Biotechnology's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of ObeTherapy Biotechnology and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of ObeTherapy Biotechnology
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of ObeTherapy Biotechnology and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • ObeTherapy Biotechnology Snapshot
    • ObeTherapy Biotechnology Overview
    • Key Information
    • Key Facts
  • ObeTherapy Biotechnology - Research and Development Overview
    • Key Therapeutic Areas
  • ObeTherapy Biotechnology - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • ObeTherapy Biotechnology - Pipeline Products Glance
    • ObeTherapy Biotechnology - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • ObeTherapy Biotechnology - Drug Profiles
    • Antisense RNAi Oligonucleotide to Inhibit Apobec-1 for Obesity
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OBE-1999
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OBE-2000
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OBE-2001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OBE-2002
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Obesity
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • ObeTherapy Biotechnology - Pipeline Analysis
  • ObeTherapy Biotechnology - Pipeline Products by Target
  • ObeTherapy Biotechnology - Pipeline Products by Molecule Type
  • ObeTherapy Biotechnology - Pipeline Products by Mechanism of Action
  • ObeTherapy Biotechnology - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • ObeTherapy Biotechnology, Key Information
  • ObeTherapy Biotechnology, Key Facts
  • ObeTherapy Biotechnology - Pipeline by Indication, 2015
  • ObeTherapy Biotechnology - Pipeline by Stage of Development, 2015
  • ObeTherapy Biotechnology - Monotherapy Products in Pipeline, 2015
  • ObeTherapy Biotechnology - Preclinical, 2015
  • ObeTherapy Biotechnology - Discovery, 2015
  • ObeTherapy Biotechnology - Pipeline by Target, 2015
  • ObeTherapy Biotechnology - Pipeline by Molecule Type, 2015
  • ObeTherapy Biotechnology - Pipeline Products by Mechanism of Action, 2015

List of Figures

  • ObeTherapy Biotechnology - Pipeline by Stage of Development, 2015
  • ObeTherapy Biotechnology - Monotherapy Products in Pipeline, 2015
  • ObeTherapy Biotechnology - Pipeline by Top 10 Target, 2015
  • ObeTherapy Biotechnology - Pipeline by Top 10 Molecule Type, 2015
  • ObeTherapy Biotechnology - Pipeline Products by Top 10 Mechanism of Action, 2015
k
Back to Top